CR Double-Crane(SH:600062) Cai Jing Wang·2025-08-12 13:12Core Viewpoint - China Resources Double Crane announced the establishment of a biopharmaceutical industry fund with a target fundraising scale of 500 million RMB, aiming to enhance its strategic layout in synthetic biology and promote innovation and commercialization of products and technologies [1][4]. Group 1: Fund Details - The fund, named China Resources Double Crane Biopharmaceutical Industry Fund (Hohhot), will have a total investment of 50 million RMB, with the company and its wholly-owned subsidiary contributing up to 87 million RMB, accounting for no more than 17.40% of the total fund [1][4]. - The fund's partners include various entities, with China Resources Double Crane Pharmaceutical Co., Ltd. contributing 83 million RMB, representing 16.60% of the total fund [3]. Group 2: Strategic Objectives - The establishment of the fund is part of the company's strategic direction towards synthetic biology, aiming to leverage synergies with Hohhot's industrial development and enhance investment methods in key areas [4]. - The fund is expected to facilitate innovation incubation, accelerate product and technology collaboration, and secure commercial rights for products [4].